Research programme: gastrointestinal disease therapeutics - Auriga/DegussaAlternative Names: Gastrointestinal disease therapeutics - Auriga/Degussa
Latest Information Update: 16 Jul 2016
At a glance
- Originator Auriga Laboratories; Degussa
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Germany (PO, Controlled release)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA (PO, Controlled release)
- 22 Aug 2006 Preclinical trials in Inflammatory bowel disease in Germany (PO)